BRISBANE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, CEO and
President of InterMune, will present at the Canaccord Adams 28th Annual Global
Growth Conference in Boston on August 13, 2008 at 1:00 p.m. EDT.
To access a live audio webcast of the presentation, investors and other
interested parties may log on to the investor relations page of InterMune's
corporate website at http://www.intermune.com. The company recommends logging
on to the site 15 minutes prior to the start of the presentation in order to
register or download any necessary software.
About InterMune
InterMune is a biotechnology company focused on the research, development
and commercialization of innovative therapies in pulmonology and hepatology.
InterMune has a research and development portfolio addressing idiopathic
pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The
pulmonology portfolio includes the Phase 3 program, CAPACITY, which is
evaluating pirfenidone for the treatment of patients with IPF and a research
program focused on small molecules for pulmonary disease. The hepatology
portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to
as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor
research program, and a research program evaluating a new target in
hepatology. For additional information about InterMune and its R&D pipeline,
please visit http://www.intermune.com.
SOURCE InterMune, Inc.
